Nektar Therapeutics (NKTR) Free cash flow 2016–2025
Nektar Therapeutics (NKTR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$208.7MFY2025 · since FY2016: -$123.4M → -$208.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$208.7M | -17.8% |
| FY2024 | -$177.2M | +8.4% |
| FY2023 | -$193.5M | +37.5% |
| FY2022 | -$309.7M | +27.6% |
| FY2021 | -$427.6M | -33.4% |
| FY2020 | -$320.5M | +9.7% |
| FY2019 | -$355.0M | -150.4% |
| FY2018 | $704.0M | +881.4% |
| FY2017 | -$90.1M | +27.0% |
| FY2016 | -$123.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice